Cyclopamine Was Absurdly Easy Previously, But These Days It Is Close To Impossible

The high frequency of the neurological symptoms in our patients previously treated by nelarabine strongly suggested the association of the nelarabine use. Furthermore, the HLA-haploidentical SCT setting and the use of a potentially neurotoxic agent, HDAC might augment the neurotoxicity of nelarabine. It may be desirable that HLA-haploidentical SCT candidates http://www.selleckchem.com/products/BI-2536.html avoid receiving nelarabine. Am. J. Hematol. 88:853�C857, 2013. ? 2013 Wiley Periodicals, Inc. Severe peripheral neuropathy and myelopathy are rare complications after stem cell transplantation (SCT). SCT of unmanipulated bone marrow (BM) and peripheral blood stem cell (PBSC) from HLA-haploidentical familial donors (HLA-haploidentical SCT) using only pharmacological GVHD prophylaxis has been investigated in our institution [1, 2]. In both myeloablative conditioning (MAC) and reduced intensity conditioning (RIC), the rate of Grade II or higher acute GVHD was kept at low level (36.7% in MAC and 20.0% in RIC, respectively) by the early therapeutic intervention for GVH reaction or Grade I GVHD, and that of extended type chronic GVHD was also low (29.2% in MAC and 25.0% in RIC, respectively). Except for the relatively high rate of viral hemorrhagic cystitis (36.7% in MAC and 42.3% http://www.selleck.cn/products/gsk126.html in RIC, respectively), other complications including neurotoxicity were at the acceptable levels, indicating that the HLA-haploidentical SCT was feasible procedure. Seven recipients of HLA-haploidentical SCT in our institution had received nelarabine therapy to control their precursor T lymphoblastic leukemia/lymphoma (T-ALL/LBL). Among evaluable six patients, three developed irreversible neurological defects in both lower extremities early after SCT (day +18 to +24) as we describe here. We discuss the etiologies of their neurological symptoms and examine their association with the use of nelarabine. Seven patients http://www.selleckchem.com/products/Cyclopamine.html with T-ALL/LBL (3 T-ALL, 4 T-LBL) who had been treated by nelarabine to control their diseases received HLA-haploidentical SCT between November 2008 and July 2012. One of them, who had already received SCTs twice from HLA-identical donors, developed pulmonary hemorrhage requiring intubation and multiple organ failure on day +7, and also resulting the death on day +35, and was considered not to be evaluable. Therefore, the remaining six patients were analyzed. The characteristics of the six patients are shown in Table 1. Disease status at the HLA-haploidentical SCT was primary refractory disease in three patients, refractory relapse in two, and second CR in one. In all five nonCR patients, BM involvement was positive. Prior to the SCT, cerebrospinal fluid (CSF) involvement was not detected in any patients. Various chemotherapies as shown in Table 1 were performed and the intra-thecal (IT) chemotherapies containing methotrexate (MTX) and cytarabine (Ara-C) were administered only at the prophylaxis doses.